Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: A series of 49 patients and review of the literature

Medicine (United States)

Volumn 93, Issue 24, 2014, Pages 340-349

  Comarmond, Cloé ^a,b,c   Crestani, Bruno ^d   Tazi, Abdellatif ^d   Hervier, Baptiste ^a,c   Adam Marchand, Sylvain ^e   Nunes, Hilario ^d   Cohen Aubart, Fleur ^f   Wislez, Marie ^g   Cadranel, Jacques ^h   Housset, Bruno ⁱ   Lloret Linares, Célia ^f   Sève, Pascal ^j   Pagnoux, Christian ^a,b,c   Abad, Sébastien ^k   Camuset, Juliette ^l   Bienvenu, Boris ^m   Duruisseaux, Michaël ⁿ   Hachulla, Eric ^o   Arlet, Jean Benoît ^p   Hamidou, Mohammed ^p   Mahr, Alfred ^p   Resche Rigon, Matthieu ^p   Brun, Anne Laure ^c   Grenier, Philippe ^c   Cacoub, Patrice ^q   Saadoun, David ^a,b,c   more..

^a Unit of Dermatology   (France)

^b CNRS   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e UNIVERSITÉ DE TOURS   (France)

^f AVICENNE HOSPITAL   (France)

^g CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^h HÔPITAL LARIBOISIÈRE   (France)

ⁱ CROIX ROUSSE HOSPITAL   (France)

^j CENTRE HOSPITALIER VICTOR DUPOUY   (France)

^k CAEN UNIVERSITY HOSPITAL   (France)

^l GRENOBLE UNIVERSITY HOSPITAL   (France)

^m UNIV LILLE   (France)

ⁿ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^o HÔTEL DIEU   (France)

^p UNIVERSITÉ PARIS DESCARTES   (France)

^q UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; RITUXIMAB;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; CAUSE OF DEATH; CHRONIC RESPIRATORY FAILURE; CLINICAL ARTICLE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; EOSINOPHIL COUNT; FEMALE; FOLLOW UP; GLOMERULONEPHRITIS; GRANULOMA; HEART INFARCTION; HUMAN; HYPEREOSINOPHILIA; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INTERSTITIAL PNEUMONIA; KIDNEY BIOPSY; KIDNEY FAILURE; LUNG FIBROSIS; LUNG FUNCTION; LUNG LAVAGE; MAINTENANCE THERAPY; MALE; MULTICENTER STUDY; MUSCLE BIOPSY; NASAL BIOPSY; NERVE BIOPSY; OPEN LUNG BIOPSY; OUTCOME ASSESSMENT; OXYGEN THERAPY; PNEUMOCYSTIS PNEUMONIA; PNEUMOMEDIASTINUM; PNEUMOTHORAX; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RELAPSE; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SKIN BIOPSY; SURVIVAL RATE; TOTAL LUNG CAPACITY; VASCULITIS; WEGENER GRANULOMATOSIS; WEIGHT REDUCTION; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CLINICAL TRIAL; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; LUNG FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY FIBROSIS; RADIOGRAPHY;

AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; BRONCHOALVEOLAR LAVAGE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84926022712     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000217     Document Type: Article

References (44)

1. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165:277- 304.
2. Ayars GH, Altman LC, Gleich GJ, et al. Eosinophil- and eosinophil granule-mediated pneumocyte injury. J Allergy Clin Immunol. 1985;76:595-604.
3. Becker-Merok A, Nossent JC, Ritland N. Fibrosing alveolitis predating microscopic polyangiitis. Scand J Rheumatol. 1999;28:254-256.
4. Bhanji A, Karim M. Pulmonary fibrosis-an uncommon manifestation of anti-myeloperoxidase-positive systemic vasculitis? NDT Plus. 2010;3:351-353.
5. Birnbaum J, Danoff S, Askin FB, Stone JH. Microscopic polyangiitis presenting as a "pulmonary-muscle" syndrome: is subclinical alveolar hemorrhage the mechanism of pulmonary fibrosis? Arthritis Rheum. 2007;56:2065-2071.
6. Du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184:459-466.
7. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002;165:1581-1586.
8. Chen M, Yu F, Zhang Y, et al. Characteristics of Chinese patients with Wegener's granulomatosis with anti-myeloperoxidase autoantibodies. Kidney Int. 2005;68:2225-2229.
9. Eschun GM, Mink SN, Sharma S. Pulmonary interstitial fibrosis as a presenting manifestation in perinuclear antineutrophilic cytoplasmic antibody microscopic polyangiitis. Chest. 2003;123:297-301.
10. Fathi M, Dastmalchi M, Rasmussen E, et al. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004;63:297-301.
11. Fauci AS, Katz P, Haynes BF, Wolff SM. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med. 1979;301:235-238.
12. Fernandez Casares M, Gonzalez A, Caputo F, et al. [Pulmonary fibrosis associated with anti-neutrophil cytoplasmic antibody positive vasculitis.]. Medicina (Mex). 2012;72:329-331.
13. Foulon G, Delaval P, Valeyre D, et al. ANCA-associated lung fibrosis: analysis of 17 patients. Respir Med. 2008;102:1392-1398.
14. Guillevin L, Pagnoux C, Seror R, et al., French Vasculitis Study Group (FVSG). The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011;90:19-27.
15. Guilpain P, Chereau C, Goulvestre C, et al. The oxidation induced by antimyeloperoxidase antibodies triggers fibrosis in microscopic polyangiitis. Eur Respir J Off J Eur Soc Clin Respir Physiol. 2011;37:1503-1513.
16. Gunnarsson R, Aaløkken TM, Molberg Ø, et al. Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study. Ann Rheum Dis. 2012;71:1966-1972.
17. Hervier B, Pagnoux C, Agard C, et al. Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature. Ann Rheum Dis. 2009;68:404-407.
18. Hiromura K, Nojima Y, Kitahara T, et al. Four cases of antimyeloperoxidase antibody-related rapidly progressive glomerulonephritis during the course of idiopathic pulmonary fibrosis. Clin Nephrol. 2000;53:384-389.
19. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116:488-498.
20. Homma S, Matsushita H, Nakata K. Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides. Respirol Carlton Vic. 2004;9:190-196.
21. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187-192.
22. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1-11.
23. Jones RB, Tervaert JWC, Hauser T, et al., European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211-220.
24. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35:1322-1328.
25. Lynch DA, Travis WD, Mü ller NL, et al. Idiopathic interstitial pneumonias: CT features. Radiology. 2005;236:10-21.
26. MacDonald SL, Rubens MB, Hansell DM, et al. Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. Radiology. 2001;221:600-605.
27. Mansi IA, Opran A, Sondhi D, et al. Microscopic polyangiitis presenting as idiopathic pulmonary fibrosis: is anti-neutrophilic cytoplasmic antibody testing indicated? Am J Med Sci. 2001;321:201-202.
28. Miloslavsky EM, Specks U, Merkel PA, et al., Rituximab in ANCAAssociated Vasculitis-Immune Tolerance Network Research Group. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2013;65:2441-2449.
29. Nada AK, Torres VE, Ryu JH, et al. Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients. Mayo Clin Proc Mayo Clin. 1990;65:847-856.
30. Nakabayashi K, Fujioka Y, Nagasawa T, et al. Dual myeloperoxidase- antineutrophil cytoplasmic antibody- and antiglomerular basement membrane antibody-positive cases associated with prior pulmonary fibrosis: a report of four cases. Clin Exp Nephrol. 2011;15:226-234.
31. Nozu T, Kondo M, Suzuki K, et al. A comparison of the clinical features of ANCA-positive and ANCA-negative idiopathic pulmonary fibrosis patients. Respir Int Rev Thorac Dis. 2009;77: 407-415.
32. Pagnoux C, Mahr A, Hamidou MA, et al., French Vasculitis Study Group. Azathioprine or methotrexate maintenance for ANCAassociated vasculitis. N Engl J Med. 2008;359:2790-2803.
33. Ryerson CJ, Hartman T, Elicker BM, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest. 2013;144:234-240.
34. Shiraki A, Ando M, Shindoh J, et al. [Prevalence of myeloperoxidase- anti-neutrophil cytoplasmic antibody (MPO-ANCA) in patients with interstitial pneumonia.]. Nihon Kokyuki Gakkai Zasshi J Jpn Respir Soc. 2007;45:921-926.
35. Souid M, Terki NH, Nochy D, Hillion D. Myeloperoxidase anti-neutrophil cytoplasmic autoantibodies (MPO-ANCA)-related rapidly progressive glomerulonephritis (RPGN) and pulmonary fibrosis (PF) with dissociated evolution. Clin Nephrol. 2001;55:337- 338.
36. Stone JH, Merkel PA, Spiera R, et al., RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221-232.
37. Streho M, Sable-Fourtassou R, Brion MC, et al. [Churg-Strauss syndrome and pulmonary fibrosis: an unusual association.]. Presse Medicale Paris Fr. 19832006;35:1259-1262.
38. Takahashi K, Suda S, Takayama M, et al. [A case of MPO ANCA associated glomerulonephritis with interstitial pneumonitis complicated with lung tuberculosis and pericarditis.]. Nihon Jinzo Gakkai Shi. 2000;42:591-596.
39. Takato H, Yasui M, Waseda Y, et al. A case of microscopic polyangiitis following mycoplasma infection in a patient with MPO-ANCA positive pulmonary fibrosis. Allergol Int Off J Jpn Soc Allergol. 2011;60:93-96.
40. Takeda Y, Aoki A, Tsuji T, et al. [A case of non-specific interstitial pneumonia in patient with microscopic polyangiitis.]. Ryumachi Rheum. 2003;43:654-659.
41. Tzelepis GE, Kokosi M, Tzioufas A, et al. Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respir J Off J Eur Soc Clin Respir Physiol. 2010;36:116-121.
42. Tzouvelekis A, Zacharis G, Oikonomou A, et al. Combined pulmonary fibrosis and emphysema associated with microscopic polyangiitis. Eur Respir J. 2012;40:505-507.
43. Watanabe T, Matsushita H, Uji M, et al. [A case of interstitial pneumonia preceding microscopic polyangiitis.]. Nihon Kokyuki Gakkai Zasshi J Jpn Respir Soc. 2007;45:615-620.
44. Young JD, Peterson CG, Venge P, Cohn ZA. Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature. 1986;321:613-616.